Autolus Therapeutics (AUTL) Operating Income (2018 - 2025)
Historic Operating Income for Autolus Therapeutics (AUTL) over the last 8 years, with Q3 2025 value amounting to -$71.6 million.
- Autolus Therapeutics' Operating Income fell 551.74% to -$71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$273.9 million, marking a year-over-year decrease of 2518.31%. This contributed to the annual value of -$241.4 million for FY2024, which is 3434.87% down from last year.
- Autolus Therapeutics' Operating Income amounted to -$71.6 million in Q3 2025, which was down 551.74% from -$61.2 million recorded in Q2 2025.
- Autolus Therapeutics' 5-year Operating Income high stood at -$40355.0 for Q3 2021, and its period low was -$75.9 million during Q4 2024.
- Its 5-year average for Operating Income is -$44.4 million, with a median of -$39.9 million in 2021.
- Per our database at Business Quant, Autolus Therapeutics' Operating Income surged by 9990.55% in 2021 and then plummeted by 9244615.29% in 2022.
- Autolus Therapeutics' Operating Income (Quarter) stood at -$23.1 million in 2021, then skyrocketed by 49.57% to -$11.6 million in 2022, then crashed by 357.26% to -$53.3 million in 2023, then crashed by 42.41% to -$75.9 million in 2024, then rose by 5.59% to -$71.6 million in 2025.
- Its Operating Income stands at -$71.6 million for Q3 2025, versus -$61.2 million for Q2 2025 and -$65.2 million for Q1 2025.